Sera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $52,550.28 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CFO Austin Aerts sold 7,179 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $7.32, for a total transaction of $52,550.28. Following the completion of the transaction, the chief financial officer now directly owns 291,486 shares in the company, valued at approximately $2,133,677.52. The trade was a 2.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Austin Aerts also recently made the following trade(s):

• On Tuesday, September 10th, Austin Aerts sold 5,056 shares of Sera Prognostics stock. The shares were sold at an average price of $7.57, for a total transaction of $38,273.92.

Sera Prognostics Price Performance

SERA opened at $6.44 on Friday. The business’s fifty day simple moving average is $7.38 and its 200 day simple moving average is $7.64. Sera Prognostics, Inc. has a 52 week low of $1.67 and a 52 week high of $12.35.

Sera Prognostics (NASDAQ:SERA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the company posted ($0.23) earnings per share. As a group, analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Sera Prognostics

Large investors have recently added to or reduced their stakes in the business. Quest Partners LLC grew its stake in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after buying an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Sera Prognostics in the second quarter worth about $68,000. SG Americas Securities LLC purchased a new position in Sera Prognostics during the 3rd quarter valued at about $78,000. Prime Capital Investment Advisors LLC purchased a new position in Sera Prognostics during the 3rd quarter valued at about $104,000. Finally, MetLife Investment Management LLC lifted its holdings in Sera Prognostics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock worth $135,000 after buying an additional 9,722 shares during the period. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.